Data and analytics company, GlobalData, has revealed 2017 was a record-breaking year for the number of approvals of biosimilars.
Along (bio)similar lines
In the report ‘Number of biosimilars first approved each year in the US, Japan or EU, 2013–2017’, it was highlighted that last year the US Food and Drug Administration (FDA) alone approved five new biosimilar products. These approvals raised the number of biosimilars available on the US market from four to nine and included two products for oncology use — Mylan and Biocon’s Ogivri, which is a biosimilar to Genentech’s Herceptin and Amgen and Allergan’s Mvasi, which is a biosimilar to Genentech’s Avastin.